Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC
Traded as NASDAQ: JAZZ
Industry Biotechnology
Headquarters Dublin, Ireland
Key people
Bruce C. Cozadd
(Chairman and CEO)
Kathryn E. Falberg
(CFO and Executive Vice President)
Suzanne Sawochka Hooper
(Executive Vice President and General Counsel)
Russell J. Cox
(Chief Commercial Officer) and Executive Vice President)
Products Xyrem, FazaClo, FazaClo HD, Luvox CR, Prialt
Revenue Increase $340.9 million Q3 2015[1]
Increase $159.3 million Q3 2015[1]
Website www.jazzpharma.com

Jazz Pharmaceuticals PLC (a merger of Jazz Pharmaceuticals and Azur Pharma PLC) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug, Xyrem (Sodium Oxybate - another term for the identical substance more commonly referred to as GHB Gamma Hydroxy Butrate).

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

Company history & Acquisitions


On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia[5] In the following December, a new patent was issued for Sodium Oxybate [6]


On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge[7]


On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments[8] In September the company successfully sold its Women's Health business to Meda for $95 million [9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia [10]


In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion[11][12]


In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largesr acqusition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14]

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Jazz Pharmaceuticals

(Merged 2011)

Jazz Pharmaceuticals

Azur Pharma PLC

EUSA Pharma
(Acq 2012)

Gentium SpA
(Acq 2014)

Alizé Pharma II
(Acq 2016)

Celator Pharmaceuticals
(Acq 2016)



This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.